Vivos Therapeutics ( (VVOS) ) has released a notification of late filing.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vivos Therapeutics, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The delay is primarily due to the recent acquisition of The Sleep Center of Nevada, which requires additional time for auditing and integration of financial statements. The company expects to file the report within the five-day extension period allowed by the SEC. Financially, Vivos anticipates a significant increase in general and administrative expenses, leading to a material rise in net loss for the quarter compared to the previous year, largely due to one-time acquisition costs. The company remains committed to compliance, with CFO Bradford Amman signing off on the notification.
The most recent analyst rating on (VVOS) stock is a Buy with a $6.60 price target. To see the full list of analyst forecasts on Vivos Therapeutics stock, see the VVOS Stock Forecast page.
Spark’s Take on VVOS Stock
According to Spark, TipRanks’ AI Analyst, VVOS is a Neutral.
Vivos Therapeutics’ overall score is driven by its financial struggles and valuation concerns, despite promising strategic moves and positive technical indicators. The acquisition of The Sleep Center of Nevada and strategic pivots provide potential growth avenues, but significant financial risks remain.
To see Spark’s full report on VVOS stock, click here.
More about Vivos Therapeutics
Average Trading Volume: 763,195
Technical Sentiment Signal: Buy
Current Market Cap: $27.98M
See more insights into VVOS stock on TipRanks’ Stock Analysis page.